<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>minutemed.ai ‚Äî Simplified Paper Summaries</title>
  <meta name="description" content="MinuteMed.ai: med-focused summaries of scientific papers with three reading levels (Beginner, Medium, Pro)." />

  <style>
    :root{
      /* White + green + orange theme (light, clinical, approachable) */
      --bg:#ffffff;
      --surface:#ffffff;
      --surface2:#f6fbf7;          /* faint green tint */
      --text:#0f172a;              /* slate-900 */
      --muted:#475569;             /* slate-600 */
      --border:#e2e8f0;            /* slate-200 */
      --shadow: 0 10px 30px rgba(15, 23, 42, .08);

      --green:#16a34a;             /* green-600 */
      --greenSoft:#e9f9ee;         /* soft green background */
      --orange:#f97316;            /* orange-500 */
      --orangeSoft:#fff3e9;        /* soft orange background */

      --radius:16px;
      --max: 1180px;
    }

    *{box-sizing:border-box}
    body{
      margin:0;
      font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji","Segoe UI Emoji";
      background:
        radial-gradient(1200px 650px at 15% 0%, rgba(22,163,74,.10), transparent 60%),
        radial-gradient(900px 600px at 85% 10%, rgba(249,115,22,.10), transparent 55%),
        var(--bg);
      color:var(--text);
      line-height:1.55;
    }
    a{color:var(--green); text-decoration:none}
    a:hover{text-decoration:underline}
    .container{max-width:var(--max); margin:0 auto; padding:22px}

    header{
      position:sticky; top:0; z-index:20;
      backdrop-filter: blur(10px);
      background: rgba(255,255,255,.82);
      border-bottom:1px solid rgba(226,232,240,.9);
    }
    .topbar{
      max-width:var(--max);
      margin:0 auto;
      padding:14px 22px;
      display:flex; gap:12px; align-items:center; justify-content:space-between;
    }
    .brand{display:flex; align-items:center; gap:10px; font-weight:850; letter-spacing:.2px}
    .logo{
      width:36px; height:36px; border-radius:12px;
      background: linear-gradient(135deg, rgba(22,163,74,.95), rgba(249,115,22,.9));
      box-shadow: 0 10px 24px rgba(22,163,74,.12);
    }
    .brand small{
      display:block;
      font-weight:650;
      color:var(--muted);
      letter-spacing:0;
      margin-top:2px;
      font-size:12px;
    }

    .search{
      flex:1; max-width:600px;
      display:flex; gap:10px; align-items:center;
      background: rgba(255,255,255,.95);
      border:1px solid var(--border);
      padding:10px 12px; border-radius:999px;
      box-shadow: 0 8px 20px rgba(15,23,42,.05);
    }
    .search input{
      width:100%; background:transparent; border:0; outline:0; color:var(--text);
      font-size:14px;
    }
    .chip{
      display:inline-flex; align-items:center; gap:8px;
      padding:6px 10px; border:1px solid var(--border);
      border-radius:999px; color:var(--muted); font-size:12px;
      background: rgba(241,245,249,.75);
      white-space:nowrap;
    }
    .btn{
      padding:10px 12px; border-radius:14px;
      border:1px solid var(--border);
      background: rgba(255,255,255,.95);
      color:var(--text);
      cursor:pointer;
      box-shadow: 0 8px 20px rgba(15,23,42,.05);
    }
    .btn:hover{border-color:#cbd5e1}
    @media (max-width: 980px){
      .topbar{flex-wrap:wrap}
      .search{order:3; flex-basis:100%; max-width:none}
    }

    .grid{
      display:grid; gap:18px;
      grid-template-columns: 1.22fr .78fr;
      align-items:start;
    }
    @media (max-width: 980px){ .grid{grid-template-columns: 1fr} }

    .card{
      background: linear-gradient(180deg, rgba(255,255,255,.98), rgba(246,251,247,.98));
      border:1px solid var(--border);
      border-radius: var(--radius);
      box-shadow: var(--shadow);
      overflow:hidden;
    }
    .pad{padding:18px}
    .divider{height:1px; background:rgba(226,232,240,.95); margin:14px 0}

    .h1{font-size:22px; line-height:1.2; margin:0 0 10px; letter-spacing:.1px}
    .meta{display:flex; flex-wrap:wrap; gap:10px; color:var(--muted); font-size:13px}
    .meta span{display:inline-flex; gap:6px; align-items:center}

    .section h2{
      font-size:13px; letter-spacing:.15em; text-transform:uppercase;
      color:#334155; /* slate-700 */
      margin:0 0 10px;
    }

    .pill{
      display:inline-flex; align-items:center; gap:8px;
      padding:7px 10px; border-radius:999px;
      border:1px solid var(--border);
      background: rgba(241,245,249,.7);
      font-size:12px; color:var(--muted);
    }
    .badge{
      display:inline-flex; align-items:center;
      padding:6px 10px; border-radius:999px;
      border:1px solid var(--border);
      background: rgba(241,245,249,.7);
      font-size:12px; color:var(--muted);
    }
    .badge.good{
      border-color: rgba(22,163,74,.25);
      background: var(--greenSoft);
      color: #166534; /* green-800 */
    }
    .badge.warn{
      border-color: rgba(249,115,22,.25);
      background: var(--orangeSoft);
      color: #9a3412; /* orange-800 */
    }

    .tabs{
      display:flex; gap:8px; flex-wrap:wrap;
      border:1px solid var(--border);
      background: rgba(241,245,249,.55);
      padding:8px;
      border-radius: 999px;
      width:fit-content;
    }
    .tab{
      border:1px solid transparent;
      background: transparent;
      color: #334155;
      padding:8px 12px;
      border-radius:999px;
      cursor:pointer;
      font-weight:800;
      font-size:13px;
    }
    .tab[aria-selected="true"]{
      background: rgba(22,163,74,.12);
      color: #14532d;
      border-color: rgba(22,163,74,.22);
    }
    .tab[data-level="pro"][aria-selected="true"]{
      background: rgba(249,115,22,.12);
      color: #7c2d12;
      border-color: rgba(249,115,22,.22);
    }
    .tab:focus{
      outline:2px solid rgba(22,163,74,.35);
      outline-offset:2px;
    }

    .list{margin:0; padding-left:18px}
    .list li{margin:8px 0}
    .small{font-size:13px; color:var(--muted)}

    .kpi{
      display:grid; gap:10px;
      grid-template-columns: repeat(3, minmax(0, 1fr));
      margin-top:12px;
    }
    @media (max-width: 650px){ .kpi{grid-template-columns: 1fr} }
    .kpi .box{
      border:1px solid var(--border);
      background: rgba(255,255,255,.9);
      border-radius: 14px;
      padding:12px;
    }
    .kpi .label{color:var(--muted); font-size:12px}
    .kpi .value{font-size:16px; font-weight:900; margin-top:4px}

    .paperGrid{display:grid; gap:12px}
    .paperItem{
      border:1px solid var(--border);
      background: rgba(255,255,255,.95);
      border-radius: 14px;
      padding:14px;
      cursor:pointer;
      transition: transform .08s ease, border-color .08s ease, box-shadow .08s ease;
      box-shadow: 0 8px 18px rgba(15,23,42,.05);
    }
    .paperItem:hover{transform: translateY(-1px); border-color:#cbd5e1; box-shadow: 0 10px 22px rgba(15,23,42,.07)}
    .paperTitle{margin:0 0 6px; font-size:15px; line-height:1.25}
    .paperSub{margin:0; color:var(--muted); font-size:13px}
    .row{display:flex; gap:8px; flex-wrap:wrap; margin-top:10px}

    .hidden{display:none !important}

    .paperlist{display:grid; gap:12px}
    .paperitem{
      border:1px solid var(--border);
      background: rgba(255,255,255,.95);
      border-radius: 14px;
      padding:12px;
      box-shadow: 0 8px 18px rgba(15,23,42,.05);
    }
    .paperitem h3{margin:0 0 6px; font-size:14px}
    .paperitem p{margin:0; color:var(--muted); font-size:13px}

    footer{padding:26px 0; color:var(--muted); font-size:13px}

    .kbd{
      font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace;
      border:1px solid var(--border);
      background: rgba(241,245,249,.75);
      padding:2px 7px;
      border-radius:8px;
      font-size:12px;
      color:#334155;
    }
  </style>
</head>

<body>
<header>
  <div class="topbar">
    <div class="brand" role="banner">
      <div class="logo" aria-hidden="true"></div>
      <div>
        minutemed.ai
        <small>Paper ‚Üí practice, in minutes</small>
      </div>
    </div>

    <div class="search" role="search" aria-label="Search papers">
      <span class="small" aria-hidden="true">üîé</span>
      <input id="searchInput" type="search" placeholder="Search papers, conditions, drugs‚Ä¶ (static demo)" />
      <span class="chip">Try: ‚ÄúGLP-1‚Äù</span>
    </div>

    <button id="homeBtn" class="btn" type="button" title="Back to paper list">Home</button>
  </div>
</header>

<main class="container">
  <div class="grid">
    <!-- MAIN -->
    <section aria-label="Main content">
      <!-- HOME: list of relevant papers -->
      <article id="homeView" class="card section">
        <div class="pad">
          <h2>Currently relevant</h2>
          <p class="small" style="margin:0 0 12px;">
            Click a paper to open it. Then choose a reading level:
            <strong>Beginner</strong> (anyone can understand),
            <strong>Medium</strong> (some scientific language; assumes basic background),
            or <strong>Pro</strong> (full scientific detail).
          </p>

          <div class="divider"></div>

          <div id="paperList" class="paperGrid" aria-label="Paper list"></div>
        </div>
      </article>

      <!-- DETAIL: paper page -->
      <article id="detailView" class="card hidden" aria-label="Paper detail">
        <div class="pad">
          <div style="display:flex; justify-content:space-between; gap:12px; flex-wrap:wrap; align-items:flex-start;">
            <div>
              <h1 id="paperTitle" class="h1"></h1>
              <div id="paperMeta" class="meta"></div>
              <div id="paperTags" class="row"></div>
            </div>
            <div class="row">
              <span id="paperStatus" class="badge good">‚óè Relevant</span>
              <span id="paperDate" class="badge">Updated: ‚Äî</span>
            </div>
          </div>

          <div class="divider"></div>

          <div class="section">
            <h2>Choose your level</h2>
            <div class="tabs" role="tablist" aria-label="Reading level">
              <button class="tab" role="tab" id="tab-beginner" aria-controls="panel-beginner" aria-selected="true" data-level="beginner">
                Beginner
              </button>
              <button class="tab" role="tab" id="tab-medium" aria-controls="panel-medium" aria-selected="false" data-level="medium">
                Medium
              </button>
              <button class="tab" role="tab" id="tab-pro" aria-controls="panel-pro" aria-selected="false" data-level="pro">
                Pro
              </button>
            </div>
            <p class="small" style="margin:12px 0 0;">
              Keyboard: <span class="kbd">1</span> Beginner, <span class="kbd">2</span> Medium, <span class="kbd">3</span> Pro,
              <span class="kbd">Esc</span> back to the list.
            </p>
          </div>

          <div class="divider"></div>

          <!-- Panels (content is rendered dynamically; headings remain consistent) -->
          <div id="panel-beginner" class="section" role="tabpanel" aria-labelledby="tab-beginner" data-panel="beginner"></div>
          <div id="panel-medium" class="section hidden" role="tabpanel" aria-labelledby="tab-medium" data-panel="medium"></div>
          <div id="panel-pro" class="section hidden" role="tabpanel" aria-labelledby="tab-pro" data-panel="pro"></div>
        </div>
      </article>
    </section>

    <!-- SIDEBAR -->
    <aside aria-label="Sidebar">
      <div class="card">
        <div class="pad section">
          <h2>How to use MinuteMed</h2>
          <ul class="list">
            <li><strong>Home</strong> shows papers people are actively discussing (high-impact trials, practice-changing results, and notable translational work).</li>
            <li>Click a paper ‚Üí pick your level ‚Üí skim the same headings every time.</li>
            <li><strong>Beginner</strong> focuses on the ‚Äústory‚Äù and what it means. <strong>Medium</strong> adds methods + key terminology. <strong>Pro</strong> adds deeper mechanism + critique.</li>
          </ul>

          <div class="divider"></div>

          <h2>Consistent headings</h2>
          <p class="small" style="margin:0;">
            Every level uses the same structure:
            <strong>TL;DR</strong>, <strong>The Big Question</strong>, <strong>How they tested it (Methods)</strong>,
            <strong>What they found (Results)</strong>, <strong>Limitations & caveats</strong>, <strong>Discussion questions</strong>, <strong>Citations</strong>.
          </p>
        </div>
      </div>

      <div class="card" style="margin-top:18px;">
        <div class="pad section">
          <h2>Up next</h2>
          <div class="paperlist">
            <div class="paperitem">
              <h3>Feature idea: ‚ÄúWhat changes Monday?‚Äù</h3>
              <p>A practical box: what a clinician would do differently after reading the paper.</p>
            </div>
            <div class="paperitem">
              <h3>Feature idea: ‚ÄúMechanism map‚Äù</h3>
              <p>One clean pathway diagram per paper (drug ‚Üí target ‚Üí physiology ‚Üí patient outcome).</p>
            </div>
            <div class="paperitem">
              <h3>Feature idea: ‚ÄúCompare trials‚Äù</h3>
              <p>Side-by-side endpoints for competing interventions (who wins, who loses, and why).</p>
            </div>
          </div>
        </div>
      </div>
    </aside>
  </div>

  <footer class="container" style="padding-left:0; padding-right:0;">
    <div class="divider"></div>
    <p style="margin:0;">
      ¬© <span id="year"></span> minutemed.ai ‚Äî Static demo layout (list ‚Üí paper ‚Üí reading level).
    </p>
  </footer>
</main>

<script>
  /*
    NOTE:
    - The ‚Äúcurrently relevant‚Äù papers below are examples for layout + content structure.
    - Replace titles, DOIs, PubMed IDs, and text with the exact papers you want to feature.
  */

  const PAPERS = [
    {
      id: "paper-1-select-semaglutide",
      relevance: "Hot",
      updated: "2026-02-15",
      title: "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)",
      journal: "N Engl J Med",
      year: "2023",
      design: "Cardiovascular outcomes randomized controlled trial (CVOT)",
      sample: "n = 17,604",
      area: "Cardiology ‚Ä¢ Obesity medicine",
      tags: ["Semaglutide", "MACE", "Secondary prevention", "Obesity"],
      evidenceBadge: { tone:"good", text:"Evidence: Large RCT" },
      links: [
        { label: "DOI", url: "https://doi.org/10.1056/NEJMoa2307563" },
        { label: "PubMed", url: "https://pubmed.ncbi.nlm.nih.gov/37952131/" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"People with obesity have a higher risk of heart attacks and strokes." },
            { label:"What was tested?", value:"Semaglutide vs placebo in people with heart disease who do not have diabetes." },
            { label:"Bottom line", value:"Semaglutide lowered the chance of major heart problems." }
          ],
          tldr: [
            "This study asked a simple question: if someone has obesity and already has heart disease, can a weight-loss medication also lower the risk of serious heart events‚Äîeven if the person does not have diabetes?",
            "In a very large group of patients, people taking semaglutide had fewer major cardiovascular events (like heart attack, stroke, or cardiovascular death) than people taking placebo.",
            "The take-home message is that obesity treatment can overlap with heart-disease prevention, not just weight change for appearance."
          ],
          bigQuestion: [
            "Can treating obesity with a medication meaningfully reduce heart attacks and strokes in high-risk patients without diabetes?",
            "If benefits are real, should this kind of therapy be viewed as part of cardiovascular prevention rather than only a weight-loss tool?"
          ],
          methods: [
            "Researchers enrolled adults who had overweight/obesity and established cardiovascular disease, but did not have diabetes.",
            "Participants were randomly assigned to receive semaglutide or placebo and were followed over time.",
            "They tracked major cardiovascular events and also monitored weight change and side effects."
          ],
          results: [
            "The semaglutide group had fewer major cardiovascular events compared with placebo.",
            "Participants on semaglutide typically lost weight and often showed improvements in other risk factors that influence heart health.",
            "Side effects were mostly gastrointestinal (for example, nausea), and some patients stopped treatment because of tolerability."
          ],
          limitations: [
            "This was a high-risk group (people who already had heart disease), so results may not automatically apply to lower-risk patients.",
            "Long-term benefit depends on staying on therapy; many real-world patients discontinue or cycle on/off medication.",
            "Cost, access, and insurance coverage strongly influence how much impact this could have at the population level."
          ],
          discussion: [
            "Should semaglutide be considered a cardiovascular prevention therapy in obesity, similar to how we think about statins?",
            "Which patients are most likely to benefit, and which patients are least likely to tolerate the medication?",
            "If someone stops the medication, how quickly do the benefits fade, and what follow-up plan makes sense?"
          ],
          citations: [
            "Lincoff AM, et al. N Engl J Med. 2023;389:2221‚Äì2232. doi:10.1056/NEJMoa2307563."
          ]
        },
        medium: {
          kpi: [
            { label:"Design", value:"Large CVOT randomized controlled trial" },
            { label:"Population", value:"Established CVD + overweight/obesity, without diabetes" },
            { label:"Primary endpoint", value:"MACE (composite cardiovascular outcomes)" }
          ],
          tldr: [
            "SELECT tested whether a GLP-1 receptor agonist (semaglutide) reduces major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight/obesity, without diabetes.",
            "The trial showed a statistically significant reduction in MACE with semaglutide versus placebo, supporting cardiometabolic benefit beyond glucose lowering.",
            "Clinically, the study reframes obesity pharmacotherapy as risk modification in secondary prevention‚Äîwhile highlighting tolerability, persistence, and access as major real-world constraints."
          ],
          bigQuestion: [
            "Does GLP-1‚Äìbased therapy reduce hard cardiovascular endpoints in obesity independent of diabetes status?",
            "How much of the effect is mediated by weight loss versus improvements in blood pressure, lipids, inflammation, or direct vascular mechanisms?"
          ],
          methods: [
            "High-risk adults with established cardiovascular disease and overweight/obesity (without diabetes) were randomized to semaglutide or placebo.",
            "The primary outcome was time to first major adverse cardiovascular event (a composite endpoint).",
            "Safety and tolerability were tracked with attention to gastrointestinal adverse events and discontinuation."
          ],
          results: [
            "Semaglutide reduced MACE compared with placebo, demonstrating benefit in a non-diabetic obesity population.",
            "Weight reduction was substantial, and cardiometabolic risk factors generally improved in patterns consistent with GLP-1 therapy.",
            "Discontinuation due to adverse events is clinically relevant, because persistence strongly influences effectiveness outside trials."
          ],
          limitations: [
            "External validity is strongest for secondary prevention; generalizing to primary prevention requires additional evidence.",
            "Composite endpoints can obscure which components drive the signal; component-level interpretation matters.",
            "Implementation barriers (coverage, dose escalation, patient support) may reduce observed benefit at scale."
          ],
          discussion: [
            "How should semaglutide be prioritized alongside other evidence-based secondary-prevention therapies?",
            "Which patient features predict maximal benefit (baseline BMI, visceral adiposity, inflammatory burden, comorbidity profile)?",
            "What strategies improve persistence: slower titration, symptom management, or structured follow-up?"
          ],
          citations: [
            "Lincoff AM, et al. N Engl J Med. 2023;389:2221‚Äì2232. doi:10.1056/NEJMoa2307563."
          ]
        },
        pro: {
          kpi: [
            { label:"Clinical impact", value:"Obesity pharmacotherapy as secondary cardiovascular prevention" },
            { label:"Mechanistic debate", value:"Weight-mediated vs direct vascular/inflammatory pathways" },
            { label:"Pragmatics", value:"Persistence and access are the main limiting steps" }
          ],
          tldr: [
            "SELECT demonstrates that GLP-1 receptor agonism (semaglutide) reduces MACE in a non-diabetic cohort with established CVD and overweight/obesity, extending cardiometabolic outcome benefits beyond glycemic contexts.",
            "The causal architecture likely integrates adiposity reduction, hemodynamic effects (blood pressure), lipid shifts, inflammatory modulation, and possibly direct vascular/endothelial pathways; disentangling mediation remains complex.",
            "From a translational standpoint, the key determinants of real-world effect size are treatment persistence, adverse-event management, equitable coverage, and appropriate risk-based patient selection."
          ],
          bigQuestion: [
            "What mechanistic phenotype (inflammatory, metabolic, hemodynamic) best predicts MACE reduction with semaglutide in non-diabetic obesity?",
            "How should semaglutide be sequenced with other cardioprotective therapies to maximize net benefit while minimizing treatment burden and discontinuation?"
          ],
          methods: [
            "Event-driven CVOT design with adjudicated endpoints and robust longitudinal follow-up.",
            "Randomization minimizes confounding; secondary analyses can explore heterogeneity but must avoid overinterpretation.",
            "Safety evaluation includes tolerability, dose escalation dynamics, and discontinuation patterns that influence effectiveness."
          ],
          results: [
            "A significant reduction in MACE supports cardioprotection in non-diabetic obesity within secondary prevention.",
            "Downstream improvements in weight and cardiometabolic markers provide plausible mediators, although mediation analysis is non-trivial.",
            "Adverse-event‚Äìrelated discontinuation is not just a side note; it is central to implementation and comparative effectiveness."
          ],
          limitations: [
            "Generalizability to primary prevention, younger cohorts, or lower baseline risk requires dedicated studies.",
            "The composite endpoint may mask differential effects across MI, stroke, and CV death; component-level risk reductions matter clinically.",
            "Population-level impact is highly sensitive to real-world uptake, persistence, and payer policy."
          ],
          discussion: [
            "Should future trials target primary prevention or focus on identifying maximal-response subgroups within secondary prevention?",
            "Which biomarkers (hsCRP, visceral adiposity proxies, cardiometabolic panels) best predict benefit and guide prioritization?",
            "How should systems operationalize persistence (nurse-led titration, standardized nausea protocols, structured follow-up)?"
          ],
          citations: [
            "Lincoff AM, et al. N Engl J Med. 2023;389:2221‚Äì2232. doi:10.1056/NEJMoa2307563."
          ]
        }
      }
    },

    {
      id: "paper-2-tirzepatide-osa",
      relevance: "Trending",
      updated: "2026-02-15",
      title: "Tirzepatide for obstructive sleep apnea in adults with obesity",
      journal: "N Engl J Med",
      year: "2024",
      design: "Randomized placebo-controlled trials",
      sample: "Adults with moderate-to-severe OSA and obesity",
      area: "Pulm/Sleep ‚Ä¢ Obesity medicine",
      tags: ["OSA", "Tirzepatide", "GLP-1/GIP", "AHI", "Hypoxic burden"],
      evidenceBadge: { tone:"good", text:"Evidence: RCTs" },
      links: [
        { label: "DOI", url: "https://doi.org/10.1056/NEJMoa2404881" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"Sleep apnea causes repeated breathing pauses during sleep and leads to daytime fatigue." },
            { label:"What was tested?", value:"A medication that produces major weight loss (tirzepatide) vs placebo." },
            { label:"Bottom line", value:"Sleep apnea severity improved in many patients." }
          ],
          tldr: [
            "Obstructive sleep apnea often gets worse with obesity because extra tissue and changes in airway mechanics make the throat more likely to collapse during sleep.",
            "These studies tested whether tirzepatide‚Äîan injectable medication that helps people lose a meaningful amount of weight‚Äîcould also improve sleep apnea.",
            "Compared with placebo, people taking tirzepatide had fewer breathing interruptions at night and reported improvements that suggest the changes were noticeable in real life, not just on a sleep study."
          ],
          bigQuestion: [
            "If obesity drives sleep apnea for many people, can weight-loss medications reduce sleep apnea severity in a meaningful way?",
            "Could some patients reduce their dependence on devices like CPAP if the underlying driver improves?"
          ],
          methods: [
            "Adults with obesity and moderate-to-severe obstructive sleep apnea were randomized to tirzepatide or placebo.",
            "Researchers measured sleep apnea severity using standard sleep study metrics (including the apnea‚Äìhypopnea index).",
            "They also tracked weight change, symptoms, and adverse effects."
          ],
          results: [
            "Tirzepatide reduced the number of apnea/hypopnea events and improved measures related to oxygen drops during sleep.",
            "Participants lost significant weight, which likely contributed to improved airway stability.",
            "Side effects were mostly gastrointestinal; a portion of participants discontinued treatment."
          ],
          limitations: [
            "Sleep apnea is not the same in every person; some cases are more structural/anatomic and may respond less to weight loss alone.",
            "Long-term durability depends on maintaining weight loss and/or continuing medication.",
            "Access and cost can limit real-world impact even when trial results are positive."
          ],
          discussion: [
            "Who should get medication first, CPAP first, or both together?",
            "What matters more to patients: fewer events on a sleep study, fewer symptoms, or better cardiovascular risk over time?",
            "If medication is stopped, how should clinicians monitor for relapse?"
          ],
          citations: [
            "Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. doi:10.1056/NEJMoa2404881."
          ]
        },
        medium: {
          kpi: [
            { label:"Design", value:"Randomized placebo-controlled trials" },
            { label:"Primary readouts", value:"AHI, hypoxic burden, patient-reported outcomes" },
            { label:"Interpretation", value:"Treats a major driver (obesity phenotype)" }
          ],
          tldr: [
            "Across randomized trials enrolling adults with moderate-to-severe OSA and obesity, tirzepatide reduced AHI and hypoxic burden while producing substantial weight loss and improving sleep-related patient-reported outcomes.",
            "The results support a ‚Äútreat-the-driver‚Äù approach in obesity-associated OSA: improving airway collapsibility and physiologic stress via metabolic therapy, potentially alongside device-based treatments.",
            "Implementation hinges on phenotype selection, tolerability, and defining clinically meaningful response beyond a single sleep metric."
          ],
          bigQuestion: [
            "To what extent can incretin-based pharmacotherapy meaningfully reduce OSA severity and symptom burden in obesity-associated disease?",
            "How should tirzepatide integrate with CPAP, mandibular devices, positional therapy, and lifestyle interventions?"
          ],
          methods: [
            "Adults with obesity and moderate-to-severe OSA were randomized to tirzepatide or placebo with structured follow-up.",
            "Endpoints included polysomnography-derived AHI, measures capturing hypoxic burden, weight change, and patient-reported outcomes.",
            "Safety analyses emphasized GI adverse events, dose escalation, and discontinuation."
          ],
          results: [
            "Tirzepatide reduced AHI and improved oxygen-related measures, consistent with reduced sleep-disordered breathing severity.",
            "Weight loss was substantial and plausibly mediated much of the physiologic improvement.",
            "PRO improvements suggest that benefits were clinically noticeable rather than purely numerical."
          ],
          limitations: [
            "OSA heterogeneity means obesity-targeted therapy may be less effective in non-obesity phenotypes or predominantly anatomic obstruction.",
            "AHI is an imperfect proxy for cardiovascular risk; hypoxic burden may better capture physiologic stress but is still evolving as an endpoint.",
            "Long-term comparative effectiveness vs CPAP or combination strategies requires additional trials."
          ],
          discussion: [
            "Which response threshold should guide continued therapy: symptom improvement, AHI reduction, or both?",
            "Should future trials co-primary hypoxic burden and patient-centered outcomes rather than AHI alone?",
            "What is the best monitoring strategy in practice: repeat sleep studies vs structured symptom and adherence tracking?"
          ],
          citations: [
            "Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. doi:10.1056/NEJMoa2404881."
          ]
        },
        pro: {
          kpi: [
            { label:"Phenotyping", value:"Obesity-driven collapsibility vs anatomic/loop-gain/arousal phenotypes" },
            { label:"Outcome nuance", value:"AHI vs hypoxic burden vs PROs" },
            { label:"Next steps", value:"Pragmatic, head-to-head, and CV outcome studies" }
          ],
          tldr: [
            "The tirzepatide OSA program demonstrates that large, pharmacologically induced weight loss can translate into clinically meaningful reductions in sleep-disordered breathing severity, including AHI and measures related to hypoxic burden.",
            "Mechanistically, improvements likely reflect reduced upper-airway collapsibility pressure dynamics, altered pharyngeal fat deposition, and downstream cardiometabolic and inflammatory shifts that reduce physiologic stress during sleep.",
            "The central translational challenge is phenotype stratification (who responds), endpoint selection (beyond AHI), and implementation (titration, persistence, and integration with device therapies)."
          ],
          bigQuestion: [
            "Which OSA subphenotypes derive maximal marginal benefit from incretin pharmacotherapy, and how does this interact with CPAP adherence and net cardiovascular risk reduction?",
            "Can hypoxic burden and autonomic arousal metrics outperform AHI as trial endpoints for long-term outcomes?"
          ],
          methods: [
            "Randomized placebo-controlled designs with physiologic endpoints (polysomnography) and patient-centered endpoints (PROs).",
            "Safety/tolerability assessments focused on class-related gastrointestinal adverse effects and discontinuation patterns.",
            "Secondary analyses frame how weight loss correlates with physiologic improvement, but causal mediation remains multifactorial."
          ],
          results: [
            "Reductions in AHI and improvements in oxygen-related measures support physiologic benefit, with symptom/PRO signals suggesting functional relevance.",
            "Weight loss provides a dominant mechanistic mediator, but heterogeneity implies additional pathways and varying ceiling effects.",
            "Persistence is an implementation-critical outcome: discontinuation reduces effectiveness and complicates comparative value versus CPAP."
          ],
          limitations: [
            "OSA is multi-dimensional; weight loss alone may not normalize disease in many patients, especially in anatomically constrained airways.",
            "Endpoints vary in clinical meaning: AHI reduction does not uniformly translate to cardiovascular risk reduction, and PROs can be influenced by expectations and comorbid sleep fragmentation.",
            "Pragmatic effectiveness in community settings depends on access, follow-up infrastructure, and coordinated sleep-medicine care."
          ],
          discussion: [
            "Should future OSA trials mandate phenotype stratification and use hierarchical endpoints that prioritize patient-centered function and hypoxic burden?",
            "What is the optimal combination strategy: pharmacotherapy first, CPAP first, or parallel initiation with adaptive de-escalation?",
            "How should health systems model cost-effectiveness when one therapy influences multiple comorbidities (weight, BP, inflammation, OSA severity)?"
          ],
          citations: [
            "Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. doi:10.1056/NEJMoa2404881."
          ]
        }
      }
    },

    {
      id: "paper-3-donanemab-lte",
      relevance: "Relevant",
      updated: "2026-02-15",
      title: "Donanemab in early symptomatic Alzheimer‚Äôs disease: long-term extension findings",
      journal: "Journal of Prevention of Alzheimer‚Äôs Disease (example)",
      year: "2025‚Äì2026",
      design: "Long-term extension with external comparisons (program-level evidence)",
      sample: "Multi-year follow-up (extension framework)",
      area: "Neurology ‚Ä¢ Alzheimer‚Äôs",
      tags: ["Donanemab", "Anti-amyloid", "CDR-SB", "ARIA monitoring"],
      evidenceBadge: { tone:"warn", text:"Evidence: Extension data" },
      links: [
        { label: "PubMed", url: "https://pubmed.ncbi.nlm.nih.gov/" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"Alzheimer‚Äôs gradually worsens memory and daily function over time." },
            { label:"What was tested?", value:"A drug that lowers amyloid plaques (donanemab) and its longer-term effects." },
            { label:"Bottom line", value:"Earlier treatment may be associated with slower decline, but interpretation is cautious." }
          ],
          tldr: [
            "Donanemab is designed to reduce amyloid plaques in the brain, which are one of the key features seen in Alzheimer‚Äôs disease.",
            "After the original randomized trial period, some studies follow patients longer to see how people do over multiple years and whether starting earlier may matter.",
            "These longer-term data often suggest that people treated earlier may decline more slowly, but extension studies can be harder to interpret because the comparisons are not always as clean as in the original randomized trial."
          ],
          bigQuestion: [
            "Does starting anti-amyloid therapy earlier lead to a bigger long-term benefit in day-to-day function?",
            "Can treatment be limited in duration (for example, stopping after amyloid levels are low) while keeping benefits?"
          ],
          methods: [
            "Participants who completed an initial trial may enter a long-term extension phase for additional follow-up.",
            "Some people start treatment earlier, while others start later, creating ‚Äúearly-start‚Äù and ‚Äúdelayed-start‚Äù patterns.",
            "Researchers track cognitive and functional outcomes over time and monitor safety, often with MRI to watch for ARIA."
          ],
          results: [
            "Over time, earlier exposure is often associated with slower worsening on common Alzheimer‚Äôs rating scales.",
            "Amyloid levels can decrease substantially in many participants, and some protocols allow dosing to stop once amyloid is sufficiently reduced.",
            "Safety concerns remain important, particularly MRI changes (ARIA) that require careful monitoring."
          ],
          limitations: [
            "Extension phases are not always randomized in the same way as the original trial, so comparisons may be less certain.",
            "Benefits are typically modest and must be weighed against monitoring burden and side effects.",
            "Real-world patients may be older or have comorbidities that change the risk‚Äìbenefit balance."
          ],
          discussion: [
            "Who is the best candidate: very early disease, specific biomarker profiles, or lower baseline MRI risk?",
            "What does ‚Äúmeaningful benefit‚Äù look like for patients and families over 1‚Äì3 years?",
            "How should clinicians balance safety monitoring, cost, and access when benefits are modest?"
          ],
          citations: [
            "Program-level donanemab extension publications and primary phase 3 trial reports (replace with exact citation links)."
          ]
        },
        medium: {
          kpi: [
            { label:"Design", value:"Long-term extension + early-start vs delayed-start patterns" },
            { label:"Endpoints", value:"Functional/cognitive trajectories (e.g., CDR-SB) + biomarker change" },
            { label:"Caution", value:"Extension/external comparisons limit causal inference" }
          ],
          tldr: [
            "Long-term extension analyses in anti-amyloid programs often evaluate whether earlier initiation of donanemab yields increasing clinical separation over multi-year horizons, alongside substantial amyloid reduction on imaging.",
            "These datasets can inform questions about durability and dosing strategy (including limited-duration dosing after amyloid clearance), but they do not carry the same causal strength as the original randomized controlled period.",
            "Clinically, the decision framework remains risk‚Äìbenefit: modest average benefit, meaningful for some patients, with a monitoring and ARIA-risk profile that demands infrastructure."
          ],
          bigQuestion: [
            "Does early initiation of anti-amyloid therapy produce larger cumulative clinical benefit, and what biomarker thresholds should guide stopping or restarting therapy?",
            "How do tau stage, vascular comorbidity, and baseline MRI risk features modify marginal benefit and harm?"
          ],
          methods: [
            "Extension designs follow original trial participants with continued structured assessment of cognition and function.",
            "Early-start vs delayed-start exposure patterns can be compared, sometimes supplemented by external cohort comparisons.",
            "Safety surveillance includes MRI monitoring for ARIA and standardized adverse-event capture."
          ],
          results: [
            "Clinical trajectories may show increasing separation for earlier exposure patterns over time in some analyses.",
            "Amyloid plaque burden can decrease substantially, and reaccumulation dynamics may influence stop/restart strategies.",
            "Safety monitoring remains central: ARIA and related symptoms can drive treatment interruption or discontinuation."
          ],
          limitations: [
            "Selection and attrition are common in extension phases and can bias long-term estimates.",
            "External comparisons, even with adjustment, can leave residual confounding.",
            "Average effect sizes are modest; patient-centered outcomes and caregiver impact remain critical to interpretation."
          ],
          discussion: [
            "Which biomarker package is minimally sufficient for safe real-world deployment (PET vs plasma biomarkers vs MRI-only strategies)?",
            "Should treatment be time-limited by protocol, or individualized by biomarker kinetics and tolerability?",
            "How should clinicians counsel patients about uncertainty in long-term extension evidence?"
          ],
          citations: [
            "Donanemab phase 3 publications and long-term extension analyses (replace with your chosen specific paper citations)."
          ]
        },
        pro: {
          kpi: [
            { label:"Framework", value:"Biomarker-guided dosing with complex longitudinal inference" },
            { label:"Core critique", value:"LTE/external control designs are vulnerable to residual confounding and censoring" },
            { label:"Clinical hinge", value:"ARIA risk management + infrastructure" }
          ],
          tldr: [
            "Donanemab long-horizon analyses aim to characterize whether earlier initiation yields cumulative clinical advantage and whether limited-duration dosing (after biomarker-defined amyloid clearance) is feasible without immediate loss of benefit.",
            "Analytically, extension designs and external comparators introduce risks of informative censoring, selection effects, and residual confounding, so results should be framed as supportive rather than definitive.",
            "Translation requires a rigorous operational model: patient selection by biomarker stage, MRI risk stratification, standardized ARIA monitoring, and shared decision-making around modest expected benefit versus burden and harm."
          ],
          bigQuestion: [
            "Which longitudinal causal framework (marginal structural models, joint modeling with censoring, biomarker-informed dynamic regimes) best supports inference in extension datasets?",
            "How should dosing cessation and retreatment be optimized using amyloid kinetics, tau stage, and ARIA susceptibility to maximize net benefit?"
          ],
          methods: [
            "Longitudinal follow-up with repeated cognitive/functional endpoints and imaging/biomarker measurements.",
            "Exposure patterns (early-start vs delayed-start) are compared, sometimes against external cohorts, requiring careful adjustment and sensitivity analyses.",
            "Safety programs rely on MRI surveillance and protocolized management of ARIA (interruption, dose modification, discontinuation)."
          ],
          results: [
            "Signals consistent with sustained amyloid reduction and possible cumulative clinical benefit with earlier exposure may be observed, depending on analytic approach and cohort definitions.",
            "Biomarker durability and reaccumulation remain key questions that influence time-limited dosing strategies.",
            "ARIA risk remains the central implementation barrier, shaping eligibility, monitoring cadence, and adherence."
          ],
          limitations: [
            "Extension datasets are under persistent threats: selection/attrition bias, time-varying confounding, and differential follow-up.",
            "External controls may be poorly aligned on unmeasured factors (frailty, comorbidity, practice patterns, diagnostic workup).",
            "Clinical meaning of scale changes can be patient-dependent; average treatment effects may mask meaningful heterogeneity."
          ],
          discussion: [
            "What is the most defensible stopping rule for amyloid clearance, and how should retreatment thresholds be defined?",
            "Can plasma biomarkers safely reduce reliance on PET while preserving patient selection accuracy?",
            "How should health systems prioritize access when infrastructure (PET/MRI capacity) is limited?"
          ],
          citations: [
            "Donanemab phase 3 publications and long-term extension analyses (replace with your chosen specific paper citations)."
          ]
        }
      }
    },

    {
      id: "paper-4-hcm-mavacamten",
      relevance: "Core",
      updated: "2026-02-15",
      title: "Mavacamten for obstructive hypertrophic cardiomyopathy (mechanism-targeted therapy)",
      journal: "NEJM / program-level trials (example)",
      year: "2020‚Äì2024",
      design: "Randomized trials + extension data (program evidence)",
      sample: "Symptomatic obstructive HCM cohorts",
      area: "Cardiology ‚Ä¢ HCM",
      tags: ["Mavacamten", "Myosin inhibitor", "LVOT gradient", "NYHA class"],
      evidenceBadge: { tone:"good", text:"Evidence: RCT program" },
      links: [
        { label: "PubMed", url: "https://pubmed.ncbi.nlm.nih.gov/" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"In obstructive HCM, the heart squeezes too strongly and can block blood flow out of the heart." },
            { label:"What was tested?", value:"A medication that gently ‚Äúturns down‚Äù the heart‚Äôs squeezing (mavacamten)." },
            { label:"Bottom line", value:"Many patients had less blockage and felt better." }
          ],
          tldr: [
            "Obstructive hypertrophic cardiomyopathy (HCM) can cause shortness of breath, chest pain, and exercise limitation because the thickened heart muscle and strong contraction create a dynamic blockage to blood leaving the heart.",
            "Mavacamten is a medication designed to reduce excessive contraction by changing how the heart‚Äôs muscle proteins generate force.",
            "Across major studies, patients often showed less obstruction and improved symptoms, but the medication must be monitored because too much ‚Äúturning down‚Äù can reduce pumping strength."
          ],
          bigQuestion: [
            "If we treat the core mechanism (excessive contraction), can we improve symptoms and reduce obstruction more directly than older therapies?",
            "Can medication reduce the need for invasive procedures in selected patients?"
          ],
          methods: [
            "Patients with symptomatic obstructive HCM were assigned to mavacamten or placebo in randomized trials.",
            "Researchers measured obstruction (using echocardiography) and tracked symptoms and exercise capacity.",
            "Safety monitoring included watching the heart‚Äôs pumping function to avoid excessive reduction in contraction."
          ],
          results: [
            "Many patients showed reductions in obstruction and improvements in functional status or exercise measures.",
            "Symptom improvement is clinically meaningful because it impacts daily life and activity tolerance.",
            "Careful titration and follow-up imaging are used to keep the medication in a safe and effective range."
          ],
          limitations: [
            "Not every HCM patient has the same mechanism; some symptoms are driven more by diastolic dysfunction or arrhythmias.",
            "Results from trial populations may differ from community practice depending on monitoring and adherence.",
            "Long-term outcomes and optimal sequencing with procedures are still being refined."
          ],
          discussion: [
            "Which patients should start medication versus proceeding directly to a procedure?",
            "How should clinicians balance symptom relief with the need for ongoing echocardiographic monitoring?",
            "What outcomes matter most: symptoms, gradients, hospitalization, or long-term remodeling?"
          ],
          citations: [
            "Mavacamten pivotal trials and follow-up analyses (replace with the exact paper you want to feature)."
          ]
        },
        medium: {
          kpi: [
            { label:"Mechanism", value:"Cardiac myosin inhibition reduces hypercontractility and dynamic LVOT obstruction" },
            { label:"Key readouts", value:"LVOT gradient, NYHA class, exercise capacity, PROs" },
            { label:"Safety hinge", value:"EF surveillance and dose titration" }
          ],
          tldr: [
            "Mavacamten targets the sarcomere by inhibiting cardiac myosin, reducing the probability of force-generating actin‚Äìmyosin interactions and thereby attenuating hypercontractility in obstructive HCM.",
            "Randomized trials show improvements in physiologic endpoints (LVOT gradients) and clinically meaningful outcomes (functional class, exercise measures, and patient-reported symptoms) compared with placebo in selected cohorts.",
            "Clinical implementation depends on structured titration and echocardiographic monitoring because excessive negative inotropy can lower ejection fraction."
          ],
          bigQuestion: [
            "Can a mechanism-targeted sarcomere therapy produce durable, patient-centered benefit while maintaining safety across real-world monitoring conditions?",
            "Which phenotypes (baseline gradient severity, mitral anatomy, fibrosis burden) derive the greatest marginal benefit?"
          ],
          methods: [
            "Randomized placebo-controlled trial designs enrolling symptomatic obstructive HCM participants with defined gradient thresholds.",
            "Dose titration strategies guided by echocardiographic parameters and systolic function.",
            "Outcomes include LVOT gradient changes, functional class, exercise capacity, and safety events."
          ],
          results: [
            "Improvements in LVOT gradients align with the mechanistic hypothesis of reduced hypercontractility.",
            "Functional and symptom measures improve in a meaningful proportion of patients, supporting translation beyond surrogate endpoints.",
            "Safety signals are manageable with monitoring protocols, but implementation quality is a determinant of effectiveness."
          ],
          limitations: [
            "Trial selection criteria may exclude higher-risk or more complex patients, limiting generalizability.",
            "HCM symptomatology is multifactorial; gradient reduction is not always sufficient for full symptom relief.",
            "Long-term comparative effectiveness versus procedures and combination therapy requires ongoing evidence."
          ],
          discussion: [
            "What should be the threshold for declaring response: gradient reduction, symptom improvement, or both?",
            "How should mavacamten be sequenced with beta-blockers, disopyramide, or septal reduction therapy?",
            "What is the best minimal monitoring schedule that preserves safety in routine practice?"
          ],
          citations: [
            "Mavacamten pivotal trials and follow-up analyses (replace with the exact paper you want to feature)."
          ]
        },
        pro: {
          kpi: [
            { label:"Sarcomere kinetics", value:"Shift of myosin away from force-generating states reduces net cross-bridge cycling" },
            { label:"Physiology linkage", value:"Hypercontractility ‚Üí SAM/LVOT obstruction ‚Üí exertional limitation" },
            { label:"Implementation", value:"Dose-response and EF trajectory monitoring" }
          ],
          tldr: [
            "Mavacamten operationalizes a sarcomere-level strategy in obstructive HCM by modulating myosin head availability and reducing force-generating cross-bridge formation, thereby decreasing contractility and dynamic obstruction (LVOT gradients) in appropriately selected patients.",
            "Clinical benefit in trials reflects translation across a mechanistic chain (sarcomere kinetics ‚Üí LVOT hemodynamics ‚Üí functional capacity and symptom burden), but effect heterogeneity is expected given variation in anatomy, fibrosis, and diastolic properties.",
            "The key practical constraint is maintaining a therapeutic window: enough myosin inhibition to reduce gradients and symptoms, without inducing clinically meaningful systolic dysfunction‚Äîhence the centrality of protocolized titration and EF surveillance."
          ],
          bigQuestion: [
            "Which structural and molecular phenotypes (myofilament energetics, fibrosis burden, mitral apparatus geometry) best predict response and safety margins?",
            "Can long-term therapy modify remodeling trajectories, arrhythmia burden, or progression to heart failure phenotypes?"
          ],
          methods: [
            "Randomized programs with echo-guided titration to achieve target gradient reduction while preserving systolic function.",
            "Composite endpoints integrate physiologic and patient-centered outcomes; careful adjudication of safety and discontinuation is required.",
            "Longitudinal follow-up (including extensions) informs durability and retreatment/maintenance dosing strategies."
          ],
          results: [
            "Hemodynamic improvement (gradient reduction) is consistent with reduced hypercontractility, with associated improvements in symptoms and exercise measures in many patients.",
            "Safety remains primarily related to negative inotropy; monitoring protocols mitigate risk but require real-world fidelity.",
            "Program data support mechanism-targeted therapy as a major addition to HCM management, with ongoing refinement of candidacy and sequencing."
          ],
          limitations: [
            "Mechanistic benefit can be attenuated by non-obstructive drivers (diastolic dysfunction, microvascular ischemia, atrial fibrillation) that persist despite gradient improvement.",
            "Endpoint interpretation can be complicated by placebo effects in symptom scales and variable exercise testing performance.",
            "Long-term net benefit depends on persistence, monitoring, and integration with structural therapies in complex cases."
          ],
          discussion: [
            "Should future trials incorporate advanced imaging (CMR fibrosis quantification) into response stratification?",
            "What is the optimal algorithm for dose titration using gradients and EF without over-monitoring?",
            "How should comparative effectiveness be measured against septal reduction therapy in matched phenotypes?"
          ],
          citations: [
            "Mavacamten pivotal trials and follow-up analyses (replace with the exact paper you want to feature)."
          ]
        }
      }
    }
  ];

  // Consistent headings across levels
  const SECTION_ORDER = [
    { key: "tldr", title: "TL;DR" },
    { key: "bigQuestion", title: "The Big Question" },
    { key: "methods", title: "How they tested it (Methods)" },
    { key: "results", title: "What they found (Results)" },
    { key: "limitations", title: "Limitations & caveats" },
    { key: "discussion", title: "Discussion questions" },
    { key: "citations", title: "Citations" }
  ];

  // Elements
  const yearEl = document.getElementById("year");
  const homeView = document.getElementById("homeView");
  const detailView = document.getElementById("detailView");
  const paperListEl = document.getElementById("paperList");
  const searchInput = document.getElementById("searchInput");
  const homeBtn = document.getElementById("homeBtn");

  const paperTitleEl = document.getElementById("paperTitle");
  const paperMetaEl = document.getElementById("paperMeta");
  const paperTagsEl = document.getElementById("paperTags");
  const paperStatusEl = document.getElementById("paperStatus");
  const paperDateEl = document.getElementById("paperDate");

  const tabButtons = Array.from(document.querySelectorAll("[data-level]"));
  const panels = {
    beginner: document.getElementById("panel-beginner"),
    medium: document.getElementById("panel-medium"),
    pro: document.getElementById("panel-pro")
  };

  function escapeHtml(str){
    return String(str)
      .replaceAll("&","&amp;").replaceAll("<","&lt;")
      .replaceAll(">","&gt;").replaceAll('"',"&quot;")
      .replaceAll("'","&#039;");
  }

  function setHash(id){
    location.hash = id ? `#${id}` : "#";
  }

  function formatDate(iso){
    const d = new Date(iso + "T00:00:00");
    const opts = { year:"numeric", month:"short", day:"2-digit" };
    return d.toLocaleDateString(undefined, opts);
  }

  function relevanceTone(relevance){
    if (relevance === "Hot") return "good";
    if (relevance === "Trending") return "warn";
    if (relevance === "Core") return "good";
    return "good";
  }

  function renderPaperList(items){
    paperListEl.innerHTML = "";
    items.forEach(p => {
      const ev = p.evidenceBadge || { tone:"warn", text:"Evidence: ‚Äî" };
      const item = document.createElement("div");
      item.className = "paperItem";
      item.setAttribute("role","button");
      item.setAttribute("tabindex","0");
      item.setAttribute("aria-label", `Open paper: ${p.title}`);
      item.addEventListener("click", () => openPaper(p.id));
      item.addEventListener("keydown", (e) => {
        if (e.key === "Enter" || e.key === " ") openPaper(p.id);
      });

      item.innerHTML = `
        <div style="display:flex; justify-content:space-between; gap:10px; flex-wrap:wrap;">
          <div style="min-width:240px; flex:1;">
            <h3 class="paperTitle">${escapeHtml(p.title)}</h3>
            <p class="paperSub">
              ${escapeHtml(p.journal)} ‚Ä¢ ${escapeHtml(p.year)} ‚Ä¢ ${escapeHtml(p.area)}
            </p>
          </div>
          <div class="row" style="align-items:flex-start; justify-content:flex-end;">
            <span class="badge ${relevanceTone(p.relevance)}">‚óè ${escapeHtml(p.relevance)}</span>
            <span class="badge ${escapeHtml(ev.tone)}">${escapeHtml(ev.text)}</span>
          </div>
        </div>
        <div class="row">
          ${(p.tags || []).slice(0,4).map(t => `<span class="pill">${escapeHtml(t)}</span>`).join("")}
        </div>
      `;
      paperListEl.appendChild(item);
    });

    if (!items.length){
      paperListEl.innerHTML = `
        <div class="paperItem" style="cursor:default;">
          <h3 class="paperTitle">No matches found</h3>
          <p class="paperSub">Try a different keyword (for example, ‚ÄúOSA‚Äù, ‚ÄúMACE‚Äù, ‚ÄúHCM‚Äù, or ‚Äúamyloid‚Äù).</p>
        </div>
      `;
    }
  }

  function renderSections(level, paper){
    const data = paper.summaries[level];

    const kpiHtml = (data.kpi && data.kpi.length) ? `
      <div class="kpi">
        ${data.kpi.map(k => `
          <div class="box">
            <div class="label">${escapeHtml(k.label)}</div>
            <div class="value">${escapeHtml(k.value)}</div>
          </div>
        `).join("")}
      </div>
      <div class="divider"></div>
    ` : "";

    const sectionHtml = SECTION_ORDER.map(s => {
      const content = data[s.key] || [];
      const list = Array.isArray(content) ? content : [content];

      if (s.key === "citations"){
        const linksHtml = (paper.links && paper.links.length)
          ? `
            <p class="small" style="margin-top:10px;">
              Links:
              ${paper.links.map(l => `<a href="${l.url}" target="_blank" rel="noreferrer">${escapeHtml(l.label)}</a>`).join(" ‚Ä¢ ")}
            </p>
          `
          : "";

        return `
          <div class="section">
            <h2>${escapeHtml(s.title)}</h2>
            <ol class="list">
              ${list.map(li => `<li>${escapeHtml(li)}</li>`).join("")}
            </ol>
            ${linksHtml}
          </div>
        `;
      }

      return `
        <div class="section">
          <h2>${escapeHtml(s.title)}</h2>
          <ul class="list">
            ${list.map(li => `<li>${escapeHtml(li)}</li>`).join("")}
          </ul>
        </div>
      `;
    }).join('<div class="divider"></div>');

    return kpiHtml + sectionHtml;
  }

  function setActiveLevel(level, paper){
    tabButtons.forEach(btn => {
      const isSelected = btn.dataset.level === level;
      btn.setAttribute("aria-selected", isSelected ? "true" : "false");
    });

    Object.entries(panels).forEach(([k, el]) => {
      el.classList.toggle("hidden", k !== level);
      if (k === level){
        el.innerHTML = renderSections(level, paper);
      }
    });
  }

  function openPaper(id){
    const paper = PAPERS.find(p => p.id === id);
    if (!paper) return;

    homeView.classList.add("hidden");
    detailView.classList.remove("hidden");

    paperTitleEl.textContent = paper.title;

    paperMetaEl.innerHTML = `
      <span>üßæ <strong>Journal:</strong> ${escapeHtml(paper.journal)}</span>
      <span>üìÖ <strong>Year:</strong> ${escapeHtml(paper.year)}</span>
      <span>üß™ <strong>Design:</strong> ${escapeHtml(paper.design)}</span>
      <span>üë• <strong>Sample:</strong> ${escapeHtml(paper.sample)}</span>
      <span>üè• <strong>Area:</strong> ${escapeHtml(paper.area)}</span>
    `;

    paperTagsEl.innerHTML = (paper.tags || []).map(t => `<span class="pill">${escapeHtml(t)}</span>`).join("");

    paperStatusEl.className = `badge ${relevanceTone(paper.relevance)}`;
    paperStatusEl.textContent = `‚óè ${paper.relevance}`;

    paperDateEl.textContent = `Updated: ${formatDate(paper.updated)}`;

    setActiveLevel("beginner", paper);
    setHash(paper.id);
  }

  function goHome(){
    detailView.classList.add("hidden");
    homeView.classList.remove("hidden");
    setHash(null);
  }

  function onHashRoute(){
    const id = (location.hash || "").replace("#","");
    if (!id){ goHome(); return; }
    const exists = PAPERS.some(p => p.id === id);
    if (exists) openPaper(id);
    else goHome();
  }

  homeBtn.addEventListener("click", goHome);

  tabButtons.forEach(btn => {
    btn.addEventListener("click", () => {
      const id = (location.hash || "").replace("#","");
      const paper = PAPERS.find(p => p.id === id);
      if (!paper) return;
      setActiveLevel(btn.dataset.level, paper);
    });
  });

  document.addEventListener("keydown", (e) => {
    const inInput = e.target && (e.target.tagName === "INPUT" || e.target.tagName === "TEXTAREA");
    if (inInput) return;

    if (e.key === "Escape") { goHome(); return; }

    const id = (location.hash || "").replace("#","");
    const paper = PAPERS.find(p => p.id === id);
    if (!paper) return;

    if (e.key === "1") setActiveLevel("beginner", paper);
    if (e.key === "2") setActiveLevel("medium", paper);
    if (e.key === "3") setActiveLevel("pro", paper);
  });

  function applySearch(){
    const q = (searchInput.value || "").trim().toLowerCase();
    if (!q){ renderPaperList(PAPERS); return; }

    const filtered = PAPERS.filter(p => {
      const hay = [
        p.title, p.journal, p.year, p.design, p.sample, p.area,
        ...(p.tags || [])
      ].join(" ").toLowerCase();
      return hay.includes(q);
    });
    renderPaperList(filtered);
  }
  searchInput.addEventListener("input", applySearch);

  window.addEventListener("hashchange", onHashRoute);

  yearEl.textContent = new Date().getFullYear();
  renderPaperList(PAPERS);
  onHashRoute();
</script>
</body>
</html>
